IRIS
metadata only
Predictive biomarkers in cancer immunotherapy for genitourinary malignancies
Immunotherapy has transformed the management of genitourinary cancers, offering durable responses in selected patient groups. However, the clinical benefit of immune checkpoint inhibitors varies significantly across renal cell carcinoma, urothelial carcinoma, and prostate cancer, underscoring the ne
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The role of pathology in immunotherapy and targeted therapy for renal cell carcinoma#268874
- Combination Immunotherapy in Biochemically Recurrent Prostate Cancer#160334
- Differential impact of host-related factors on survival outcomes between IO+IO and IO+TKI in metastatic renal cell carcinoma: a multicenter retrospective study#1460362
- Immune Response to Immunotherapy in Lung Cancer: Study of Sputum and Blood Samples#812848
- Characterisation of TLR4+ Blood Cells in Patients With Solid Cancer#862083
Record · ID 1480089
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive